Comparison of Chemoradiotherapy and Radical Radiotherapy in Patients With Cervical Cancer

Publish Year: 1399
نوع سند: مقاله ژورنالی
زبان: English
View: 115

This Paper With 6 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

این Paper در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_MCIJO-4-2_003

تاریخ نمایه سازی: 15 بهمن 1399

Abstract:

Introduction: The current study aimed at comparing the results of radical radiotherapy (RT) or chemoradiotherapy (CRT) in patients with cervical cancer and evaluating the prognostic factors. Methods: CRT is the standard of care for locally advanced cervical cancer with the five-year survival rate of 30%–80%. In 1978-2006, a total of 716 patients with cervical cancer stage IB2-IVB were retrospectively analyzed for RT and CRT. In intracavitary brachytherapy, the median dose was 24 Gy and follow-up was 78 months. CRT was treated with 45 Gy external radiotherapy with cisplatin 40 mg/m2 given once a week. Results: The five-year pelvic control rate was 56.2% in the radical RT arm and 75.8% in the combined arm (P=0.01); disease-free survival and overall survival rates were 47%-56.3% (P=0.09) and 44.9%-52.5% (P=0.03), respectively. Treatment failure was detected in 317(50.5%) of 627 patients in the RT arm and in 30 (33.7%) of 89 patients in the CRT arm (Chi-squared value=8.86, P<0.01). Treatment failure rate was high in the 1st two years. Distant metastases were detected in 116 patients in the RT and 17 patients in the CRT arms. Hematological side effect rates in the CRT arm -anemia, thrombopenia, and leukopenia- were 33.7%, 13.5%, and 28.1%, respectively. The prevalence of rectitis, cystitis, and skin and subcutaneous fibrosis in the RT arm was 9.4%, 4.8%, and 2.2%, and in the CRT arm was 12.4%, 11.2%, and 13.5%, respectively. Conclusions: CRT increased pelvic control and overall survival rate based on the findings; it can be the preferred treatment modality because of its high response rate and acceptable toxicity.

Authors

Ozlem Yetmen Dogan

Department of Radiation Oncology, University of Health Sciences, Dr. Lutfi Kırdar Kartal Training and Research Hospital, Istanbul, Turkey

Ismet Sahinler

Radiation Oncology Department, Cerrahpasa Faculty of Medicine, Istanbul University- Cerrahpasa, Istanbul Turkey

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • 1. Lehman M, Thomas G. Is concurrent chemotherapy and radiotherapy the ...
  • 2. Roberts KB, Urdaneta N, Vera R, Vera ...
  • 3. Spensley S, Hunter RD, Livsey JE, Swindell R, David- son ...
  • 4. Rose PG. Locally advanced cervical carcinoma: the role of chemoradiation. ...
  • 5. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, ...
  • 6. Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, ...
  • 7. Pignon JP, Bourhis J, Domenge C, Designé L. Chemo- therapy ...
  • 8. Kaplan EL, Meier P. Nonparametric Estimation from Incom- plete Observations. ...
  • 9. Cox DR. Regression Models and Life-Tables. J Roy Stat Soc. ...
  • 10. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the ...
  • 11. Thomas G, Dembo A, Fyles A, Gadalla T, Beale F, ...
  • 12. Whitney CW, Sause W, Bundy BN, Malfetano JH, Han- nigan ...
  • 13. Wong L, Ngan H, Cheung A, Cheng D, Ng T, ...
  • 14. Pearcey R, Brundage M, Drouin P, Jeffrey J, Johnston D, ...
  • نمایش کامل مراجع